The study demonstrated that LyP‐1–functionalized multi‐walled carbon nanotubes/MBD1siRNA could be a promising candidate for tumour active targeting therapy in pancreatic cancer. This evidence concerns the gene PTPN22 and familial pancreatic carcinoma.